vs

Side-by-side financial comparison of Resolute Holdings Management, Inc. (RHLD) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $117.7M, roughly 1.3× Resolute Holdings Management, Inc.). Resolute Holdings Management, Inc. runs the higher net margin — -1.5% vs -5.5%, a 4.1% gap on every dollar of revenue. Resolute Holdings Management, Inc. produced more free cash flow last quarter ($189.2M vs $13.0M).

Resolute Mining Limited is an Australian mining corporation focused on mining operations in Africa. It is currently operating two gold mines: the Syama Gold Mine in Mali and the Mako Gold Mine in Senegal.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

RHLD vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.3× larger
TARS
$151.7M
$117.7M
RHLD
Higher net margin
RHLD
RHLD
4.1% more per $
RHLD
-1.5%
-5.5%
TARS
More free cash flow
RHLD
RHLD
$176.3M more FCF
RHLD
$189.2M
$13.0M
TARS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RHLD
RHLD
TARS
TARS
Revenue
$117.7M
$151.7M
Net Profit
$-1.7M
$-8.4M
Gross Margin
55.7%
Operating Margin
30.2%
-5.3%
Net Margin
-1.5%
-5.5%
Revenue YoY
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$-0.20
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RHLD
RHLD
TARS
TARS
Q4 25
$117.7M
$151.7M
Q3 25
$120.9M
$118.7M
Q2 25
$119.6M
$102.7M
Q1 25
$103.9M
$78.3M
Q4 24
$66.4M
Q3 24
$48.1M
Q2 24
$40.8M
Q1 24
$27.6M
Net Profit
RHLD
RHLD
TARS
TARS
Q4 25
$-1.7M
$-8.4M
Q3 25
$-231.0K
$-12.6M
Q2 25
$-611.0K
$-20.3M
Q1 25
$-3.4M
$-25.1M
Q4 24
$-23.1M
Q3 24
$-23.4M
Q2 24
$-33.3M
Q1 24
$-35.7M
Gross Margin
RHLD
RHLD
TARS
TARS
Q4 25
55.7%
Q3 25
59.0%
Q2 25
57.5%
Q1 25
52.5%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
RHLD
RHLD
TARS
TARS
Q4 25
30.2%
-5.3%
Q3 25
34.3%
-12.2%
Q2 25
34.0%
-21.6%
Q1 25
24.7%
-33.5%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Q1 24
-136.5%
Net Margin
RHLD
RHLD
TARS
TARS
Q4 25
-1.5%
-5.5%
Q3 25
-0.2%
-10.6%
Q2 25
-0.5%
-19.8%
Q1 25
-3.2%
-32.1%
Q4 24
-34.8%
Q3 24
-48.7%
Q2 24
-81.6%
Q1 24
-129.4%
EPS (diluted)
RHLD
RHLD
TARS
TARS
Q4 25
$-0.20
$-0.17
Q3 25
$-0.03
$-0.30
Q2 25
$-0.07
$-0.48
Q1 25
$-0.39
$-0.64
Q4 24
$-0.57
Q3 24
$-0.61
Q2 24
$-0.88
Q1 24
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RHLD
RHLD
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$205.5M
$417.3M
Total DebtLower is stronger
$169.8M
$72.4M
Stockholders' EquityBook value
$6.5M
$343.4M
Total Assets
$333.4M
$562.2M
Debt / EquityLower = less leverage
26.03×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RHLD
RHLD
TARS
TARS
Q4 25
$205.5M
$417.3M
Q3 25
$148.0M
$401.8M
Q2 25
$99.9M
$381.1M
Q1 25
$71.0M
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
RHLD
RHLD
TARS
TARS
Q4 25
$169.8M
$72.4M
Q3 25
$173.4M
$72.3M
Q2 25
$177.1M
$72.1M
Q1 25
$180.7M
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
RHLD
RHLD
TARS
TARS
Q4 25
$6.5M
$343.4M
Q3 25
$10.8M
$335.1M
Q2 25
$9.6M
$332.6M
Q1 25
$8.9M
$342.5M
Q4 24
$224.5M
Q3 24
$237.5M
Q2 24
$252.2M
Q1 24
$275.2M
Total Assets
RHLD
RHLD
TARS
TARS
Q4 25
$333.4M
$562.2M
Q3 25
$293.2M
$534.6M
Q2 25
$253.3M
$495.0M
Q1 25
$214.3M
$500.8M
Q4 24
$377.0M
Q3 24
$376.3M
Q2 24
$376.8M
Q1 24
$349.3M
Debt / Equity
RHLD
RHLD
TARS
TARS
Q4 25
26.03×
0.21×
Q3 25
16.01×
0.22×
Q2 25
18.42×
0.22×
Q1 25
20.38×
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RHLD
RHLD
TARS
TARS
Operating Cash FlowLast quarter
$196.1M
$19.3M
Free Cash FlowOCF − Capex
$189.2M
$13.0M
FCF MarginFCF / Revenue
160.8%
8.6%
Capex IntensityCapex / Revenue
5.8%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$313.2M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RHLD
RHLD
TARS
TARS
Q4 25
$196.1M
$19.3M
Q3 25
$59.6M
$18.3M
Q2 25
$48.9M
$-29.4M
Q1 25
$18.4M
$-20.7M
Q4 24
$-22.2M
Q3 24
$-8.7M
Q2 24
$-14.4M
Q1 24
$-37.8M
Free Cash Flow
RHLD
RHLD
TARS
TARS
Q4 25
$189.2M
$13.0M
Q3 25
$58.6M
$16.3M
Q2 25
$47.5M
$-30.4M
Q1 25
$17.8M
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
RHLD
RHLD
TARS
TARS
Q4 25
160.8%
8.6%
Q3 25
48.5%
13.8%
Q2 25
39.7%
-29.6%
Q1 25
17.1%
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
RHLD
RHLD
TARS
TARS
Q4 25
5.8%
4.2%
Q3 25
0.8%
1.6%
Q2 25
1.2%
1.0%
Q1 25
0.6%
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Q1 24
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons